Global pharma and life sciences (PLS) deal activity increased in value for the first quarter of 2017 compared to both the prior quarter and Q1 2016. Despite declining volumes quarter over quarter, the pharmaceuticals sub-sector once again led deal volumes with 27 deals in Q1 2017, totaling approximately $33.9 billion in deal value, followed by the medical devices sub-sector which had 25 deals approximating a total deal value of $8.2 billion.
Deal value for Q1 2017 was higher than the prior quarter; however, deal volume decreased. Excluding the Actelion transaction, deal value for the quarter was lower than the deal values for the two most recent quarters. While the number of deals announced in Q1 2017 was dramatically lower relative to the prior seven quarters, deal value in five of the last six quarters has been relatively stable.